StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Summit Therapeutics's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0, down 100.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$100.00M-79.8%
FY2022Dec 31, 2022$494.54M–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2024CQ4 2024Dec 31, 2024$0-100.0%
Q3 FY2024CQ3 2024Sep 30, 2024$0–
Q2 FY2024CQ2 2024Jun 30, 2024$0-100.0%
Q1 FY2024CQ1 2024Mar 31, 2024$100.00M-79.8%
Q4 FY2023CQ4 2023Dec 31, 2023$100.00M–
Q3 FY2023CQ3 2023Sep 30, 2023$0–
Q2 FY2023CQ2 2023Jun 30, 2023$100.00M–
Q4 FY2022CQ4 2022Dec 31, 2022$494.54M–

More Summit Therapeutics figures

See a number that looks wrong?